In another study initiated in October 2023, the antibody-drug conjugate [68Ga]Ga-THP-Trop2 VHH is being tested as a non-invasive approach to detect the TROP2 expression of tumor lesions in patients with solid tumors and to identify patients that would benefit from TROP2 targeting antibody–drug conjugate treatment (NCT06188468). The gene discussed is TACSTD2; the disease is neoplasm.